Type
Merger/Acquisition
Country
Belgium
Region
Région Wallonne; Prov. Brabant Wallon; Arr. Nivelles
Location of affected unit(s)
Rixensart and others
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture of pharmaceutical preparations

170 jobs
Number of planned job losses
Job loss
Announcement Date
3 December 2015
Employment effect (start)
Foreseen end date
31 December 2017

Description

Last year, the British pharmaceuticals producer GlaxoSmithKline took over the vaccine division of Novartis. As a  consequence, the enterprise is now confronted with a lot of overlap and double filled functions. The Research and Development department in Belgium is contracting by some 340 posts, the majority of them senior and skilled. Half will move to another job in GSK. The remaining 170 will leave the company.

The trade union is negotiating for priority to be given to voluntary departure and voluntary switches to part-time jobs. They indicate that social partner negotiations are taking place in an open and positive atmosphere. GSK employs 8,900 people in Belgium.


Sources

  • 3 December 2015: La Libre
  • 3 December 2015: De Tijd

Citation

Eurofound (2015), GlaxoSmithKline, Merger/Acquisition in Belgium, factsheet number 85650, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/85650.